MANILA, Philippines — The camp of Department of Public Works and Highways (DPWH) District Engineer Henry Alcantara denied accusations linking him to alleged ghost flood control projects in Bulacan, insisting he had no hand in the supposed scheme.
In a statement issued over the weekend, the Flaminiano Arroyo & Dueñas law firm, which represents Alcantara, said its client “maintains his innocence: he did not author these alleged ghost projects. Any wrongdoing was done behind his back, without his knowledge, acquiescence, or approval.”, This news data comes from:http://om.xs888999.com
The statement directly counters claims that Alcantara was the “kingpin” of the controversial projects, which authorities are now investigating for possible irregularities.

DPWH engineer denies role in Bulacan flood control ‘ghost projects’
“Engr. Alcantara will contest every accusation that he had supposedly participated in and/or benefitted from any unlawful scheme,” the law firm said, adding that he would exhaust all legal remedies, including challenging his summary dismissal from service.
The camp also vowed Alcantara’s cooperation with the ongoing investigation. “He will continue to assist the authorities in the investigation of these flood control ghost projects. We are confident that in due time, the truth will surface and Engr. Alcantara will be cleared of the baseless accusations levied against him,” the statement read.
- EU massive fine against Google draws Trump’s ire
- SC acquits suspect in 2012 killing of Dutch aid worker over doubtful testimonies
- Isko Moreno files charges against contractor over illegal demolition of sports complex in Manila
- Pasig City continues barangay aid for efficiency, ends patronage politics
- Task force cites new threats to media workers
- Sen. Go calls for round-the-clock DFA support for OFWs welfare
- Epstein victims compiling list of sexual abusers
- Maduro calls for dialogue hours after Trump’s threat
- Napolcom welcomes Nartatez’s move to recall Torre’s reassignments
- Trump plans a hefty tax on imported drugs, risking higher prices and shortages